Menu
Search
|

Menu

Close
X

MYnd Analytics Inc MYND.OQ (NASDAQ Stock Exchange Capital Market)

1.66 USD
-0.04 (-2.35%)
As of 11:39 AM EDT
chart
Previous Close 1.70
Open 1.71
Volume 1,736
3m Avg Volume 40,023
Today’s High 1.71
Today’s Low 1.66
52 Week High 5.04
52 Week Low 1.15
Shares Outstanding (mil) 5.68
Market Capitalization (mil) 9.37
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-1.246
FY17
-2.539
FY16
-10.532
FY15
-6.650
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.15
Price to Sales (TTM)
vs sector
14.27
8.04
Price to Book (MRQ)
vs sector
4.08
4.28
Price to Cash Flow (TTM)
vs sector
--
22.37
Total Debt to Equity (MRQ)
vs sector
31.43
17.43
LT Debt to Equity (MRQ)
vs sector
31.13
13.25
Return on Investment (TTM)
vs sector
-630.73
13.23
Return on Equity (TTM)
vs sector
-816.86
15.27

EXECUTIVE LEADERSHIP

George Carpenter
President, Chief Executive Officer, Since 2012
Salary: $270,000.00
Bonus: $25,000.00
Donald D'Ambrosio
Chief Financial Officer, Since 2017
Salary: $117,296.00
Bonus: $20,000.00
Geoffrey Harris
Director, Since 2015
Salary: --
Bonus: --
John Pappajohn
Director, Since 2012
Salary: --
Bonus: --
Robin Smith
Director, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Healthcare Facilities & Services
Address:

26522 La Alameda Ste 290
MISSION VIEJO   CA   92691-8579

Phone: +1949.4204400

MYnd Analytics, Inc., formerly CNS Response, Inc., is a predictive analytics company. The Company has developed a decision support tool to help physicians reduce trial and error treatment in mental health, and provide personalized care to patients. The Company provides objective clinical decision support to mental healthcare providers for the personalized treatment of behavioral disorders, including depression, anxiety, bipolar disorder, post-traumatic stress disorder (PTSD) and other non-psychotic disorders. The Company uses its neurometric platform, PEER Online, to generate Psychiatric electroencephalogram (EEG) Evaluation Registry (PEER) Reports to predict the likelihood of response by an individual to a range of medications prescribed for the treatment of behavioral disorders. As of September 30, 2016, the PEER Online database comprises over 38,000 clinical outcomes for over 10,200 patients with psychiatric or addictive problems.

SPONSORED STORIES